Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sutro Biopharma (STRO) Income from Continuing Operations (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Income from Continuing Operations for 9 consecutive years, with 144417000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 5.4% to 144417000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 10736000.0 through Dec 2025, up 554.34% year-over-year, with the annual reading at 93000.0 for FY2025, 103.94% up from the prior year.
  • Income from Continuing Operations hit 144417000.0 in Q4 2025 for Sutro Biopharma, up from 56857000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 152655000.0 in Q4 2024 to a low of 65325000.0 in Q1 2025.
  • Historically, Income from Continuing Operations has averaged 15624050.0 across 5 years, with a median of 36359500.0 in 2021.
  • Biggest five-year swings in Income from Continuing Operations: tumbled 322.82% in 2022 and later surged 391.53% in 2024.
  • Year by year, Income from Continuing Operations stood at 38125000.0 in 2021, then rose by 9.26% to 34594000.0 in 2022, then surged by 189.78% to 31057000.0 in 2023, then soared by 391.53% to 152655000.0 in 2024, then decreased by 5.4% to 144417000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for STRO at 144417000.0 in Q4 2025, 56857000.0 in Q3 2025, and 11499000.0 in Q2 2025.